R&D FOR BEHAVIOR CHANGE Collaborative development to automate and assess digital health interventions.


Learn about our views on agile science, evidence-building, patient adherence and behavior change technologies.


MEMOTEXT(R) and BioGen Idec Canada Announce Ground-Breaking Partnership to Help MS Patients

  • October 2014

TORONTO, ONTARIO — (MARKET WIRE) — 05/26/08 — Patients with Multiple Sclerosis (MS) who take the once-a-week prescription injection AVONEX® (interferon beta-1a) will now be the first in North America to benefit from a free and unique adherence solution program. BioGen Idec Canada, a subsidiary of Biogen Idec Inc., makers of AVONEX, and MEMOTEXT®, provider of personalized adherence solutions, have joined forces to help patients remember to take their medicine.

“It is no secret that one of the biggest challenges currently facing patients, their families and
the medical industry, is adherence. For some diseases, adherence rates are as low as 10-20%,” says Amos Adler, President of MEMOTEXT. “Studies show that long term adherence to treatment regimens, particularly when patients see signs of improvement, are abysmal. By providing education, live support and reminders to take medicines in a timely fashion this service will help improve quality of life over the long term.”



Back to Top